ABSTRACT
of the extensor tendons, namely the extensor carpi radialis brevis and longus, extensor digitorum, and extensor carpi ulnaris. 3 The precarious blood supply to the tendons prolongs the healing.
Conservative treatment (watchful waiting, nonsteroidal anti-inflammatory drugs, physiotherapy, counterforce bracing, local infiltration of corticosteroids, and Botox injections) has achieved fairly good outcome. 4 Surgical debridement of the affected tendons with decortication of the underlying epicondyle has been used for recalcitrant cases. 5 Platelet-rich plasma (PRP) has a 2-to 8-fold increase in platelet concentration and the α-granules of platelets contain growth factors (transforming growth factor beta, vascular endothelial growth factor, platelet-derived growth factor, and epithelial growth factor) capable of promoting the recruitment, proliferation, and differentiation of cells involved in tissue repair and regeneration. 6, 7 There are 4 types of PRP; each has 2 subtypes, based on the platelet and leukocyte counts and activation of PRP (Table 1 ).
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The use of leukocyte-rich (type-1) PRP may produce a more intense local inflammatory response and may be associated with an increased post-injection pain response. 7, [9] [10] [11] This study compared a single leukocytepoor (type-4B) PRP injection versus bupivacaine injection for recalcitrant LET.
Materials and Methods
This study was approved by the ethics committee of our hospital. Written informed consent was obtained from each patient. Between January 2011 and December 2011, 25 patients aged 27 to 50 years with painful (visual analogue scale [VAS] of >60) and recalcitrant (failed conservative treatment for >3 months) LET of the humerus were randomised to receive type-4B PRP (n=15) or bupivacaine (n=10) injection. Bony pathology was ruled out.
Patients aged <25 and >60 years who had pain secondary to radial tunnel syndrome or cervical radiculopathy, or a history of carpal tunnel syndrome or systemic disorders (diabetes, rheumatoid arthritis, or hepatitis) were excluded, as were those who had thrombocytopenia, were taking anticoagulants, or were pregnant.
Baseline platelet, red cell, and leukocyte counts were obtained before PRP preparation. 100 ml blood was collected into an anticoagulant blood bag and centrifuged at 1500 rpm for 15 minutes to separate the red cells from the rest of the components. The supernatant fluid was transferred into another blood bag. Leukocytes were filtered out using a filter (Imuguard III-PL, Terumo Penpol, Thiruvananthapuram, India) to obtain leukocytepoor PRP, with the platelet count between 6 and 8 ×10
5
/µl, and the leukocyte count a 3-log reduction.
8
Under ultrasonographic guidance, 3 ml of type-4B PRP and 0.5 ml of calcium chloride was injected into the maximum hypo-echoic area of the extensor carpi radialis brevis (ECRB) tendon using the peppering technique ( Fig.) . 7 Overall, 5 to 6 passes were made into the tendon using a single skin portal. For bupivacaine injection, 10 ml of blood was collected but not used, and 3 ml of bupivacaine and 0.5 ml of normal saline was injected in a similar fashion.
After injection, patients sat for 15 minutes with the arm supported in a sling. They were advised to rest the arm for 2 days. Taking oral paracetamol (650 mg) for pain was allowed. After 2 days, standard wrist extensor stretching was started at home for 4
Figure
Advancement of a needle into the extensor carpi radialis brevis tendon (arrow) and platelet-rich plasma is being injected (arrowhead). activity-related pain. Patients were followed up at 1, 3, 6, and 12 months by a single assessor who was blinded to the treatment used. Normality of data was tested using the onesample Komolgorov-Smirnov test. Percentage change in scores was calculated. The paired samples t test was used for within-group comparison. The independent samples t test was used for betweengroup comparison. The Wilcoxon test was used for non-normal data. All tests were 2-sided, and a p value of <0.05 was considered significant.
results
One patient in the bupivacaine group was lost to follow up and excluded from the analysis. At baseline, the PRP and bupivacaine groups were comparable in terms of mean age (38 vs. 37 years), numbers of female:male (12:3 vs. 5:4), mean duration of symptoms (12.1 Table 2 ). No patient had any complication except one patient who had vague giddiness after bupivacaine injection, which resolved within 30 minutes.
discussion
The success rate of physiotherapy and counterpressure bracing is around 87%. 12 Corticosteroid injection used to be the gold standard treatment, but it is associated with skin pigmentation, fat atrophy, and tendon rupture. 13 A surgical procedure has its own drawbacks. PRP injection is a minimally invasive yet effective treatment for LET. 7, [9] [10] [11] 14 Nonetheless, leukocyte-rich PRP may produce local inflammatory reactions. 10, 11, [15] [16] [17] At one year, improvement in pain was greater after leukocyte-poor PRP injection than bupivacaine, corticosteroid, autologous blood, or leukocyte-rich PRP injection (Table 3) . 7, [9] [10] [11] 17 In our study, none of the patients who received leukocytepoor PRP complained of an increased post-injection pain. Leukocyte-poor PRP helped decrease the injection-related pain and made the recovery more comfortable.
In our study, PRP was produced by the department of transfusion medicine in an outpatient setting. The time for preparation was around 1.5 hours, and the cost was around US$45, which is much lower than that for the commercial kits. The use of 100 ml of blood to produce 3 ml of leukocyte-poor PRP was more than the usual requirement of 30 to 60 ml. With better equipment, the amount of blood collected has been reduced to 50 ml.
Limitations of this study are that pre-and postinjection magnetic resonance imaging should have been performed to measure the affected area for quantification of improvement. In addition, the sample size was small and from a single centre and the follow-up of one year was short. The study lacked exact quantification of the growth factors being injected. Further studies to compare leukocytepoor PRP with leukocyte-rich PRP are needed, as are studies on properties, preparation techniques, and method of application of PRP. 
